首页> 外文会议>Enzyme engineering XXIV >MACHINE LEARNING TO ENGINEER ANTIBODY FRAMEWORKS FOR DEVELOPABILITY
【24h】

MACHINE LEARNING TO ENGINEER ANTIBODY FRAMEWORKS FOR DEVELOPABILITY

机译:机器学习工程师抗体框架的可开发性

获取原文
获取原文并翻译 | 示例

摘要

Monoclonal antibodies (mAbs) have revolutionized medicine in the last 20 years and today represents ~$70B/yr in total pharmaceutical sales, most notably in the areas of oncology and autoimmune disorders. The function and developability of mAbs depend on the expression, folding and integrity of their structure. Protein pharmaceuticals must be tolerant to factors such as heat, interfacial stress, aggregation, pH and more in order to reach the market. We here apply systematic variance, inductive machine learning, synthetic genes and our high-throughput transient mammalian protein expression platform to engineer a humanized lgG1 scaffold for high developability independent of the hypervariable region present in the mAb. All amino acid substitutions present in the framework of human IgG1 antibodies were derived from human sequences in the public domain databases and assembled in a set of 96 partial factorial lgG1 variants (aka 'infologs') using Design of Experiment (DoE) variable distribution. Total explored sequence diversity was ~2×1019. Hypervariable regions were derived from two commercial antibodies for a total of 2×96 genetic constructs. Synthesis of the 2×96 antibodies was done by transient transfection in HEK293 cells and purified in high throughput. Several independent machine learning algorithms were compared for cross validation and model accuracy and used to build iterative sequence-function correlation models to identify and quantify independent and/or synergistic variables affecting one or more of the developability functionalities. The study resulted in markedly improved mAbs frameworks as well as a deeper understanding on how different machine learning algorithms are dependent on different types of data sets.
机译:在过去的20年中,单克隆抗体(mAbs)彻底改变了医学,如今,药物的总销售额约为每年$ 70B,尤其是在肿瘤学和自身免疫性疾病领域。 mAb的功能和可开发性取决于其结构的表达,折叠和完整性。为了进入市场,蛋白质药物必须能够耐受热量,界面应力,聚集,pH等因素。我们在这里应用系统变异,归纳机器学习,合成基因和我们的高通量瞬时哺乳动物蛋白表达平台来工程化人源化lgG1支架,以实现独立于mAb中高变区的高可开发性。人IgG1抗体框架中存在的所有氨基酸取代均来自公共领域数据库中的人序列,并使用实验设计(DoE)变量分布组装成一组96个部分因子lgG1变体(又名“ infologs”)。探索的总序列多样性为〜2×1019。高变区来自两种商业抗体,共2×96个遗传构建体。 2×96抗体的合成是通过在HEK293细胞中瞬时转染完成的,并以高通量纯化。比较了几种独立的机器学习算法的交叉验证和模型准确性,并将其用于构建迭代序列功能相关模型,以识别和量化影响一个或多个可开发性功能的独立和/或协同变量。这项研究显着改善了mAb框架,并对不同的机器学习算法如何依赖于不同类型的数据集有了更深入的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号